View Older Stories View More Recent Stories

Oct 24, 2022 07:00AM Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Ri
Oct 20, 2022 05:00PM Castle Biosciences (CSTL) Reports New Data from DECIDE Showing Significant Role of DecisionDx-Melanoma Test Results
Oct 20, 2022 05:00PM New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure
Oct 19, 2022 07:00AM Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2
Oct 13, 2022 07:05AM Castle Biosciences Inc. (CSTL) Reports Strong Results from a Randomized Controlled Trial of TissueCypher
Oct 13, 2022 07:00AM Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended
Oct 11, 2022 07:00AM Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting
Oct 10, 2022 07:00AM Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annu
Sep 23, 2022 07:03AM Castle Biosciences Inc. (CSTL) Reports Publication Demonstrating the Integration of DecisionDx-Melanoma and Clinicopathologic Factors Provides Survival Prognoses for Patients with Cutaneous Melanoma
Sep 23, 2022 07:00AM Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients
Sep 21, 2022 07:00AM Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference
Sep 20, 2022 04:05PM  Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day
Sep 13, 2022 07:00AM Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association
Sep 1, 2022 07:00AM Castle Biosciences to Participate in Upcoming Investor Conferences
Aug 24, 2022 07:00AM Castle Biosciences to Host Investor Day on Sept. 20, 2022
Aug 8, 2022 04:05PM Castle Biosciences Reports Second Quarter 2022 Results
Aug 4, 2022 07:00AM American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus
Aug 3, 2022 07:00AM Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference
Jul 25, 2022 05:00PM Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8
Jul 25, 2022 07:00AM DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma
Jul 20, 2022 07:00AM Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma
Jul 18, 2022 07:00AM Castle Biosciences Honored with a 2022 Arizona Top Workplace Award
Jun 23, 2022 05:02PM Castle Biosciences Inc. (CSTL) Patients with Uveal Melanoma Tested with DecisionDx-UM Report Gaining Value from Test Results
Jun 23, 2022 05:00PM Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative
Jun 22, 2022 07:00AM Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022
Jun 20, 2022 07:00AM Castle Biosciences Announces Support for OHSU’s War on Melanoma™
Jun 14, 2022 07:00AM Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma
Jun 8, 2022 07:00AM Castle Biosciences to Present at the JMP Securities Life Sciences Conference
May 27, 2022 07:00AM Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award
May 25, 2022 05:00PM Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting
May 24, 2022 05:00PM TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
May 20, 2022 07:00AM  Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer
May 19, 2022 07:00AM Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC
May 10, 2022 07:00AM Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings
May 9, 2022 04:05PM Castle Biosciences Reports First Quarter 2022 Results
May 6, 2022 07:00AM Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety
May 3, 2022 05:00PM Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives
Apr 29, 2022 07:03AM Castle Biosciences Inc. (CSTL) Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests
Apr 29, 2022 07:00AM Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests
Apr 27, 2022 07:05AM Castle Biosciences Inc. (CSTL) Reports Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinica l Variables for TissueCypher Barrett’s Esophagus Test and Abil
Apr 27, 2022 07:00AM Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for TissueCypher® Barrett’s Esophagus Test and Ability to Identify Patients at High Risk
Apr 26, 2022 05:00PM Castle Biosciences Completes Acquisition of AltheaDx
Apr 25, 2022 05:00PM Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9
Apr 21, 2022 05:00PM Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Untested Patients
Apr 20, 2022 05:00PM Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress
Apr 18, 2022 07:00AM Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference
Apr 5, 2022 05:00PM Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference
Apr 4, 2022 04:07PM Castle Biosciences (CSTL) Acquires AltheaDx for $65M in Cash and Stock
Apr 4, 2022 04:05PM Castle Biosciences to Acquire AltheaDx
Mar 29, 2022 05:01PM Castle Biosciences Inc. (CSTL) Receives Advanced Diagnostic Laboratory Test Status for TissueCypher Barrett’s Esophagus Test from CMS
View More Recent Stories View Older Stories